vimarsana.com

Latest Breaking News On - Patrickd yeramian - Page 1 : vimarsana.com

SVB Leerink Lowers Amylyx Pharmaceuticals (NASDAQ:AMLX) to Market Perform

SVB Leerink downgraded shares of Amylyx Pharmaceuticals (NASDAQ:AMLX – Free Report) from an outperform rating to a market perform rating in a research report released on Monday morning, Marketbeat reports. Several other equities research analysts have also recently commented on the company. Robert W. Baird cut Amylyx Pharmaceuticals from an outperform rating to a neutral […]

Amylyx Pharmaceuticals (NASDAQ:AMLX) Earns Neutral Rating from The Goldman Sachs Group

The Goldman Sachs Group restated their neutral rating on shares of Amylyx Pharmaceuticals (NASDAQ:AMLX – Free Report) in a report released on Friday morning, Marketbeat Ratings reports. Several other brokerages have also recently issued reports on AMLX. Robert W. Baird assumed coverage on shares of Amylyx Pharmaceuticals in a report on Wednesday, January 3rd. They […]

Connor Clark & Lunn Investment Management Ltd Invests $2 28 Million in Amylyx Pharmaceuticals, Inc (NASDAQ:AMLX)

Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 124,455 shares of the company’s stock, valued at approximately $2,279,000. Connor Clark […]

Connor Clark & Lunn Investment Management Ltd Makes New $2 28 Million Investment in Amylyx Pharmaceuticals, Inc (NASDAQ:AMLX)

Connor Clark & Lunn Investment Management Ltd. bought a new stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) in the 3rd quarter, Holdings Channel.com reports. The fund bought 124,455 shares of the company’s stock, valued at approximately $2,279,000. Several other hedge funds and other institutional investors also recently made changes to their positions in […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.